Vol 31, No 2 (2024)
Image in Cardiovascular Medicine
Published online: 2024-04-26

open access

Page views 455
Article views/downloads 296
Get Citation

Connect on Social Media

Connect on Social Media

First use of the Impella 5.5 in a patient with cardiogenic shock to bridge to heart transplantation in Poland

Roman Przybylski1, Mikołaj Błaziak2, Maciej Bochenek1, Anna Jarosz2, Barbara Barteczko-Grajek2, Michał Zakliczyński1, Mateusz Sokolski1, Mateusz Garus1, Piotr Gajewski1, Gracjan Iwanek1, Tomasz Skalec2, Krzysztof Reczuch1, Wiktor Kuliczkowski1
Pubmed: 38686986
Cardiol J 2024;31(2):355-356.

Abstract

Not available

INTERVENTIONAL CARDIOLOGY

IMAGE INCARDIOVASCULAR MEDICINE

Cardiology Journal

2024, Vol. 31, No. 2, 355–356

DOI: 10.5603/cj.97518

Copyright © 2024 Via Medica

ISSN 1897–5593

eISSN 1898–018X

First use of the Impella 5.5 in a patient with cardiogenic shock to bridge to heart transplantation in Poland

Roman Przybylski1*Mikołaj Błaziak1*Maciej Bochenek1Anna Jarosz2Barbara Barteczko-Grajek2Michał Zakliczyński1Mateusz Sokolski1Mateusz Garus1Piotr Gajewski1Gracjan Iwanek1Tomasz Skalec2Krzysztof Reczuch1Wiktor Kuliczkowski1
1Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland
2Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland

Address for correspondence: Mikołaj Błaziak, MD, Institute of Heart Diseases, Wroclaw Medical University, Borowska 213 St., 50-556 Wroclaw, Poland, tel.: +48 71 733 11 12; e-mail: blaziak.mikolaj@gmail.com

Received: 20.09.2023 Accepted: 23.12.2023

*These authors contributed equally to this work.

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

A 46-year-old male with blood pressure (BP) 85/46 mmHg was admitted due to cardiogenic shock as a result of antero-lateral ST-segment elevation myocardial infarction treated by percutaneous coronary intervention of the left anterior descending artery in a remote hospital 2 days prior. Laboratory findings revealed N-terminal-proB-type natriuretic peptide 13,868 pg/mL, troponin I 338,068 pg/mL, and lactates 2.9 mmol/L. Echocardiography showed enlargement of both ventricles, a 10% of left ventricular (LV) ejection fraction, and LV thrombus, necessitating inotropic support with noradrenaline 4 mL/h, milrinone 9 mL/h, and vasopressin 1 mL/h (figure 1). The Shock Team decided to implement an intra-aortic balloon pump (IABP Teleflex), after which BP increased to 123/62 mmHg, and right heart catheterization revealed a mean pulmonary artery pressure of 36 mmHg, pulmonary capillary wedge pressure of 25 mmHg, cardiac index of 2.34 mL/min/1.73 m2, cardiac power of 0.75 W, and pulmonary artery pressure index of 1.6. The control echocardiography did not show LV thrombus; thus, the IABP was replaced with the Impella CP (Abiomed). Despite transitory improvement, hemolysis and thrombocytopenia were observed. As that time, the Impella 5.5 became available, and the Shock Team decided to upgrade the device to an axillary Impella 5.5, which was performed using a double device technique (Suppl. Video 1). Two days later, signs of hemolysis and thrombocytopenia ceased, and the patient’s condition improved, gaining full mobilization. After 17 days on Impella 5.5 support, uneventful orthotopic HTx (heart transplantation) was performed. The postoperative course was uncomplicated. After 4 months the patient was doing well with full physical activity. The Impella 5.5 provides maximal hemodynamic support with reduced risk of complications and with minimally invasive implantation.

Figure 1. A. Transthoracic echocardiography, dilated left ventricle (diastolic diameter 72 mm); B. Clots in the apex of the left ventricle; C. Fluoroscopy, Impella CP implanted through right femoral access; D. Transthoracic echocardiography, Impella CP; E. Fluoroscopy, Impella 5.5 implanted through axillary access with Impella CP still in left ventricle (double device technique); F. Transthoracic echocardiography, Impella 5.5.

Article information

Conflict of interest: None declared.
Funding: This work was supported by the subsidy no. SUBZ.A460.24.040 for the Institute of Heart Diseases, Wroclaw Medical University, Poland.